The market for autoimmune disease therapeutics is anticipated to expand from a current value of USD 54.8 billion in 2021 to USD 113.48 billion by 2028, at a compound annual growth rate (CAGR) of about 12.9%.
Autoimmune Disease Therapeutics Market: Overview
An autoimmune reaction that attacks cells and destroys body tissue results in autoimmune illnesses. Autoimmune disorders nearly never have a long-term cure and are almost invariably deadly. In the world, there are about 80 autoimmune conditions with an undetermined aetiology. Over 300 million individuals worldwide are afflicted by this illness, with women making up 70–80% of those affected. Increased awareness of these problems and rising prevalence of autoimmune illnesses are the two main factors propelling market expansion.
Autoimmune Disease Therapeutics Market: Growth Drivers
The rising incidence of autoimmune diseases raised patient awareness, and laboratory automation enabled the simultaneous diagnosis of several diagnostic tests, producing faster and more accurate results. These factors all helped fuel the expansion of the global market for autoimmune disease therapies. The result is a growth in the market. Healthy tissues, cells, and organs are destroyed as a result of the autoimmune illness. Any portion of the body can be affected, affecting function and endangering one’s life.
Autoimmune Disease Therapeutics Market: Segmentation
The medicine class, distribution method, and geographic segments make up the three segments of the global autoimmune disease therapies market.
Immunosuppressants, anti-inflammatory medications, corticosteroids, nonsteroidal anti-inflammatory medicines, and biologics are the most common pharmacological classes. With over 30% of global sales, anti-inflammatory medications are the market’s dominating product.
The four distribution channels for the market are independent pharmacies, hospitals, and clinics. Hospital spending is anticipated to increase more quickly during the forecasted timeframe.
Some of the main competitors dominating the global autoimmune disease therapeutics market include – Chugai Pharmaceutical Co. Ltd, Amgen Inc, Eli Lilly and Company, Genentech Inc, Elan Corporation Plc, F. Hoffmann-La Roche AG, Squibb Company, Merck Co. Inc, GlaxoSmithKline Plc, Bayer Schering Pharma AG, Biogen Idec Inc, Johnson Johnson Inc, and Abbott Laboratories.
The global autoimmune disease therapeutics market is divided into the following segments:
By Drug Class
Nonsteroidal Anti-Inflammatory Drugs
By Distribution Channel
Rest of Europe
Rest of Asia Pacific
Rest of Latin America
Middle East Africa
Rest of Middle East Africa
Zion Market Research
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL-FREE +1 (855) 465-4651